Vanguard Capital Management
IMNM icon

Vanguard Capital Management’s Immunome IMNM Stock Holding History

Vanguard Capital Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$96.4M Buy
4,551,289
+121,592
+3% +$2.6M ﹤0.01% 1571
2026
Q1 		$96.9M Buy
+4,429,697
New +$98.6M ﹤0.01% 1483

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management's IMNM Position: Q2 2026 in Review

Vanguard Capital Management increased its Immunome (IMNM) stake by 2.7% in Q2 2026, buying an estimated $2.6M and bringing the position to 4,551,289 shares worth $96.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1571.

Vanguard Capital Management first reported a position in IMNM in Q1 2026 and has held it in 2 quarters since. The position peaked at $96.9M in Q1 2026. 201 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Vanguard Capital Management held 4,551,289 shares of Immunome worth $96.4M as of Q2 2026.
  • Vanguard Capital Management bought 121,592 Immunome shares in Q2 2026, an estimated $2.6M.
  • Immunome made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1571 holding.
  • Vanguard Capital Management first reported a position in Immunome in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Immunome position peaked at $96.9M in Q1 2026.
  • 201 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.